stella
beta
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) — Stella
Recruiting
Back to HR Positive/HER2 Low Expression Metastatic Breast Cancer trials
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations
(3 sites)
China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong
The Second Affiliated Hospital， Shantou University Medical College, Shantou, Guangdong
Hainan Qionghai People's Hospital, Qionghai, Hainan
View full record on ClinicalTrials.gov